(S)-N-(3-(1-((6-(3,4-二甲氧基苯基)吡嗪-2-基)氨基)乙基)苯基)-5-甲基烟酰胺 | 1619931-27-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (S)-N-(3-(1-((6-(3,4-二甲氧基苯基)吡嗪-2-基)氨基)乙基)苯基)-5-甲基烟酰胺
• 英文名称: Seralutinib
• 英文别名: N-[3-[(1S)-1-[[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino]ethyl]phenyl]-5-methylpyridine-3-carboxamide
• CAS: 1619931-27-9
• 化学式: C₂₇H₂₇N₅O₃
• 分子量: 469.5
• InChiKey: JHJNPOSPVGRIAN-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  98.3
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Non-selective kinase inhibitors
  申请人：Pulmokine, Inc.

  公开号：US10246438B2

  公开（公告）日：2019-04-02

  Disclosed herein are compounds, compositions, and methods for preventing and treating proliferative diseases associated with aberrant receptor tyrosine kinase (RTK) activity. The therapeutic indications described herein more specifically relate to the non-selective inhibition of RTKs associated with vascular and pulmonary disorders.

  本文公开了用于预防和治疗与受体酪氨酸激酶（RTK）活性异常相关的增殖性疾病的化合物、组合物和方法。本文所述的治疗适应症更具体地涉及对与血管和肺部疾病相关的 RTK 的非选择性抑制。
• Combination therapy for treating pulmonary hypertension
  申请人：Pulmokine, Inc.

  公开号：US10231966B2

  公开（公告）日：2019-03-19

  The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.

  本公开描述了一种使用 PDGF 受体激酶抑制剂、PDEV 抑制剂和内皮素受体拮抗剂组合治疗肺部疾病（如肺动脉高压）的方法。这些化合物可抑制细胞生长和增殖，并针对 PAH 的潜在病理。
• NON-SELECTIVE KINASE INHIBITORS
  申请人：Pulmokine, Inc.

  公开号：EP3007689B1

  公开（公告）日：2018-03-07
• METHODS OF DETECTING AND TREATING PULMONARY HYPERTENSION
  申请人：Rensselaer Center for Translational Research, Inc.

  公开号：US20170131289A1

  公开（公告）日：2017-05-11

  The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response of a subject. The invention can also be used to identify subjects who require more aggressive therapeutic interventions or alternative treatments.
• COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION
  申请人：Pulmokine, Inc.

  公开号：US20180117039A1

  公开（公告）日：2018-05-03

  The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor, PDEV inhibitor, and an endothelin receptor antagonist. The compounds can inhibit cell growth and proliferation and target the underlying pathology of PAH.